Intraperitoneal Docetaxel With Cisplatin and TS-ONE for Gastric Cancer With Peritoneal Carcinomatosis
Status:
Completed
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
Phase I study on the maximum tolerated dose (MTD) and the recommended dose (RD) of
intraperitoneal docetaxel combined with intravenous cisplatin and oral TS-ONE in gastric
cancer patients with peritoneal carcinomatosis